The flavonoid apigenin inhibits the proliferation of prostatic stromal cells via the MAPK-pathway and cell-cycle arrest in G1/S

Maturitas

Volumn 55, Issue SUPPL. 1, 2006, Pages

  Bektic, Jasmin ^a   Guggenberger, Roman ^a   Spengler, Barbara ^b   Christoffel, Volker ^b   Pelzer, Alexandre ^a   Berger, Andreas P ^a   Ramoner, Reinhold ^a   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Bionorica AG   (Germany)

Author keywords

Apigenin; Apoptosis; Benign prostatic hyperplasia (BPH); G1 S; MAPK

Indexed keywords

APIGENIN; FLAVANOID; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MALE; PHOSPHORYLATION; PROSTATE; PROSTATECTOMY; PROTEIN EXPRESSION; STROMA CELL;

EID: 33750632619     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.06.015     Document Type: Article

References (26)

1. Thorpe A., and Neal D. Benign prostatic hyperplasia. Lancet 361 9366 (2003) 1359-1367
2. Cunha G.R., Chung L.W., Shannon J.M., Taguchi O., and Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res 39 (1983) 559-598
3. Gu F. Changes in the prevalence of benign prostatic hyperplasia in China. Chin Med J (Engl) 110 3 (1997) 163-166
4. Adlercreutz H., Honjo H., Higashi A., et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 54 6 (1991) 1093-1100
5. Adlercreutz H., Markkanen H., and Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 342 8881 (1993) 1209-1210
6. Santti R., Makela S., Strauss L., Korkman J., and Kostian M.L. Phytoestrogens: potential endocrine disruptors in males. Toxicol Ind Health 14 1-2 (1998) 223-237
7. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147 2 (1995) 295-302
8. Fotsis T., Pepper M.S., Montesano R., et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 12 4 (1998) 649-666
9. Kim H., Peterson T.G., and Barnes S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am J Clin Nutr 68 6 Suppl (1998) 1418S-1425S
10. Messina M.J., and Loprinzi C.L. Soy for breast cancer survivors: a critical review of the literature. J Nutr 131 11 Suppl (2001) 3095S-3108S
11. Hong S.J., Kim S.I., Kwon S.M., Lee J.R., and Chung B.C. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 43 2 (2002) 236-241
12. Duthie G., and Crozier A. Plant-derived phenolic antioxidants. Curr Opin Lipidol 11 1 (2000) 43-47
13. Kim Y.J., Ahn J.J., and Woo B.H. The effect of cytokine mediators on prostaglandin inhibition by human decidual cells. Am J Obstet Gynecol 179 1 (1998) 146-149
14. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., and Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 28 2 (2000) 102-110
15. Caltagirone S., Rossi C., Poggi A., et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87 4 (2000) 595-600
16. Wei H., Tye L., Bresnick E., and Birt D.F. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res 50 3 (1990) 499-502
17. Gupta S., Afaq F., and Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 287 4 (2001) 914-920
18. Horninger W., Berger A., Pelzer A., et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 5 (2004) 220-225
19. Boesch S.T., Corvin S., Zhang J., Rogatsch H., Bartsch G., and Klocker H. Modulation of the differentiation status of cultured prostatic smooth muscle cells by an alpha1-adrenergic receptor antagonist. Prostate 39 4 (1999) 226-233
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72 (1976) 248-254
21. Isaacs J.T. Role of androgens in prostatic cancer. Vitam Horm 49 (1994) 433-502
22. Cooke P.S., Young P., Hess R.A., and Cunha G.R. Estrogen receptor expression in developing epididymis, efferent ductules, and other male reproductive organs. Endocrinology 128 6 (1991) 2874-2879
23. Gupta S., Afaq F., and Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 21 23 (2002) 3727-3738
24. Bektic J., Berger A.P., Pfeil K., Dobler G., Bartsch G., and Klocker H. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 45 2 (2004) 245-251 [discussion 251]
25. Kuiper G.G., Lemmen J.G., Carlsson B., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 139 10 (1998) 4252-4263
26. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 60 8 (2000) 1051-1059